USPTO issues new patent to QLT synthetic retinoid program
The new patent entitled, ‘Retinal Derivatives and Methods for the Use Thereof for the Treatment of Visual Disorders,’ covers methods of utilizing QLT091001 to treat diseases linked with
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.